



## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Inventor: Scott, et al. ) Group Art Unit: 1646  
)  
Serial No: 10/817,423 ) Examiner: Unknown  
)  
Filed: April 2, 2004 ) Our Account No: 04-1403  
)  
Confirmation No: 1563 ) Customer No: 22827  
)  
Title: Novel Immunotherapy )

Commissioner for Patents  
U.S. Patent and Trademark Office  
Post Office Box 1450  
Alexandria, VA 22313-1450

Sir:

The following is an Information Disclosure Statement for the captioned patent application, pursuant to 37 CFR Sections 1.56, 1.97, and 1.98.

1.[x] Attached hereto is:

- a.[x] A list of materials for consideration per Rule 98(a)(1): 5 page(s)
- b.[x] A legible copy of each patent, publication, or other item listed per Rule 98(1)(2), unless not required per Rule 98 and/or as indicated on the attached list(s):  
36 item(s)
- c.[ ] For each non-English language item listed, pursuant to Rule 98(a)(3), a concise explanation of the relevance thereof as it is presently understood by the individual designated in Rule 56(c) most knowledgeable about the content of such items: \_\_\_\_\_
- [ ] Such explanation is provided in the Search Report from a corresponding application enclosed herewith along with any enclosed translation into English.

2.[x] This Information Disclosure Statement is being filed [CHECK ONE]:

- a.[x] WITHIN THREE MONTHS of the application filing date, national stage date of entry, or along with or after a request for continued examination, OR BEFORE the mailing date of a first Office Action on the merits, which ever event occurs last, WHEREFORE per Rule 97(b) NO filing fee or Rule 97(e) certificate is required.
- b.[ ] AFTER the time periods of section 2.a above, but BEFORE a Final Action, Notice of Allowance OR an action that otherwise closes prosecution, WHEREFORE PER Rule 97(c) submitted herewith is [CHECK ONE]:
- i.[ ] Certification per Rule 97(e); OR
- ii.[ ] Filing Fee per Rule 17(p) .....\$180.00
- c.[ ] AFTER a Final Action OR Notice of Allowance, but BEFORE payment of the issue fee, WHEREFORE per Rule 97(d) submitted herewith is:
- i. Certification per Rule 97(e); AND
- ii. Filing fee per Rule 17(p) .....\$180.00

3.[ ] Rule 97(e) Certification; per Rule 97(e), the undersigned certifying party make the following certification statement [CHECK ONE]:

- a.[ ] That each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement; OR
- b.[ ] That no item of information contained in this Information Disclosure Statement was cited in a foreign patent office in a counterpart foreign application and to the knowledge of the undersigned after making a reasonable inquiry, was known to any individual designated in Rule 56(c) more than three months prior to the filing of this statement.

CERTIFYING PARTY (if different from bottom signature; omission here indicates that certification is being made by signer per signature below).

Name: \_\_\_\_\_  
Address: \_\_\_\_\_

Signature: \_\_\_\_\_  
Date: \_\_\_\_\_

- 4.[x] DEPOSIT ACCOUNT AUTHORIZATION: The Commissioner is hereby authorized to charge any fee specifically authorized hereafter, or any fees in addition to the fee(s) filed, or asserted to be filed, or which should have been filed herewith or concerning any paper filed hereafter, and which may be required under Rules 16-18 (deficiency only) now or hereafter relative to this application and the resulting official document under Rule 20, or credit any overpayment, to our Account No. shown in the heading hereof for which purpose a duplicate copy of this sheet is attached. This statement does not authorize charge of the issue fee in this case.

- 5.[x] CERTIFICATE OF MAILING: This Information Disclosure Statement is being filed pursuant to [CHECK AND COMPLETE ONE]:

- a.[x] First Class Mail Certificate of Mailing under Rule 8:


I hereby certify that this correspondence and any referenced attachment and/or fee are being deposited with the United States Postal Service as first class mail in an envelope addressed to the:

Commissioner for Patents  
U.S. Patent and Trademark Office  
Post Office Box 1450  
Alexandria, VA 22313-1450

on July 13, 2004.

Sandra S. Perkins

(Typed/printed name of person mailing paper or fee)

  
(Signature of person mailing paper or fee)

- b.[ ] "Express Mail" Certificate under Rule 10:

"Express Mail" – Label No. \_\_\_\_\_  
Date of Deposit \_\_\_\_\_

I hereby certify that this paper and all attachments and any fee are being deposited with the U.S. Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to the:

Commissioner for Patents  
U.S. Patent and Trademark Office  
Post Office Box 1450  
Alexandria, VA 22313-1450.

\_\_\_\_\_  
(Typed/printed name of person mailing paper or fee)

\_\_\_\_\_  
(Signature of person mailing paper or fee)

ADDRESS:  
Post Office Box 1449  
Greenville, SC 29602 USA  
Customer ID No.: 22827  
Telephone: 864-271-1592  
Facsimile: 864-233-7342

DORITY & MANNING, ATTORNEYS AT LAW, P.A.

By: Christina L. Mangelsen, Patent Agent

Reg. No: 50,244

Signature: 

Date: July 13, 2004



(Rev. 5/92) Information Disclosure Statement List By Applicant(s) Under 37 CFR Section 1.98(a) (1) (Use several sheets if necessary)	Attorney Docket Number: CXU-407	Serial Number: 10/817,423
	Applicant: Scott, et al.	
	Filing Date: April 2, 2004 Confirmation No: 1563	Group Art Unit: 1646

- NOTE: If no indication is made in the column marked "COPY NOTE," the required legible copy of the corresponding item is submitted herewith; otherwise, a copy is not required and/or not submitted, for the following reason(s) [corresponding reason number is listed in "COPY NOTE" column]
- (1) This item is cumulative, per Rule 98(c)
  - (2) A copy of this item was previously cited by or submitted to the U.S. Patent and Trademark Office in:  
USSN \_\_\_\_\_, filed \_\_\_\_\_, or  
USSN \_\_\_\_\_, filed \_\_\_\_\_;  
Relied on under 35 U.S.C. Section 120, per Rule 98(d)
  - (3) Both reasons (1) and (2) apply
  - (4) No legible complete copy is possessed, in custody of controlled, or readily available
  - (5) Per the U.S. Patent and Trademark Office's waiver of Rule 98(a)(2)(i), the item is a U.S. patent or patent application publication, and the present application was filed after June 30, 2003.

U.S. PATENT DOCUMENTS												
EXAMINER INITIALS	PATENTEE NAME	PATENT NUMBER								ISSUE DATE	COPY NOTE	
	Jones, et al.	R	E	3	6	8	4	4		08/29/2000	5	
	Skubitz, et al.	5	2	6	6	3	2	8		11/30/1993	5	
	Imhof	5	5	3	8	7	2	5		07/23/1996	5	
	Ramamurthy, et al.	6	1	1	4	3	1	6		09/05/2000	5	
	Jones, et al.	6	2	9	4	3	5	6		09/25/2001	5	

U.S. PATENT APPLICATION PUBLICATIONS												
EXAMINER INITIALS	APPLICANT'S NAME	PUBLICATION NUMBER								PUBLICATION DATE	COPY NOTE	
	Tryggvason, et al.	0	0	4	4	8	9	9		03/06/2003	5	
	Yue, et al.	0	0	4	4	9	1	3		03/06/2003	5	
	Gerritsen, et al.	0	0	9	1	5	6	9		05/15/2003	5	
	Tryggvason, et al.	0	1	0	0	5	2	9		05/29/2003	5	
	Kalluri	0	1	0	8	5	4	0		06/12/2003	5	
	Montano, et al.	0	1	6	0	4	9	7		10/31/2002	5	
	Feige, et al.	0	1	6	8	3	6	3		11/14/2002	5	

FOREIGN PATENT DOCUMENTS														
EXAMINER INITIALS	COUNTRY	DOCUMENT NUMBER	PUBLICATION DATE	TRANSLATION			COPY NOTE							
				YES	NO	N/A								

\*"NO" means that no copy of an English language translation is within the possession, custody, or control of, or is readily available to any individual designated in Rule 56(c).



(Revised 6/92) Information Disclosure Statement List By Applicant(s) Under 37 CFR Section 1.98(a) (1) (Use several sheets if necessary)	Attorney Docket Number: CXU-407	Serial Number: 10/817,423
	Applicant: Scott, et al.	
	Filing Date: April 2, 2004 Confirmation No: 1563	Group Art Unit: 1646

EXAMINER INITIALS	OTHER DOCUMENTS Specify author (if any), Title, Pertinent Pages, Date & Place of Publication	COPY NOTE
	Abstract of Article – <i>Form and function: The laminin family of heterotrimers</i> , Holly Colognato and Peter D. Yurchenco from interscience.wiley.com (2 pages) originally in Developmental Dynamics, Vol. 218, Issue 2, 2000, pp. 213-234	
	Abstract of Article – <i>High expression level of alpha 6 integrin in human breast carcinoma is correlated with reduced survival</i> , K. Friedrichs, P. Ruiz, F. Franke, I. Gille, H. J. Terpe, and B. A. Imhof from cancerres.aacrjournals.org (3 pages) originally in Cancer Research, Vol. 51, Issue 4, pp. 901-906	
	Abstract of Article – <i>Identification of integrin-dependent and -independent cell adhesion domains in COOH-terminal globular region of laminin-5 alpha 3 chain</i> , H. Mizushima, H. Takamura, Y. Miyagi, Y. Kikkawa, N. Yamanaka, H. Yasumitus, K. Misugi, and K. Miyazaki from cgd.aacrjournals.org (4 pages) originally in Cell Growth & Differentiation, Vol. 8, Issue 9, 1997, pp. 979-987	
	Abstract of Article – <i>Integrin activation controls metastasis in human breast cancer</i> , B. Felding-Habermann, T. E. O'Toole, J. W. Smith, E. Fransvea, Z. M. Ruggeri, M. H. Ginsberg, P. E. Hughes, N. Pampori, S. J. Shattil, A. Saven, and B. M. Mueller from ncbi.nlm.nih.gov (2 pages) originally in Proc. Natl. Acad. Sci., Vol. 98, No. 4, February 13, 2001, pp. 1853-1858	
	Abstract of Article – <i>Integrin Laminin Receptors and Breast Carcinoma Progression</i> , Kathleen L. Connor, Jun Chung, Robin E. Bachelder, Arthur M. Mercurio, Isaac Rabinovitz, Leslie M. Shaw, and Taneli Tani from infotrieve.com (1 page) originally in Journal of Mammary Gland Biology and Neoplasia, Vol. 6, No. 3, 2001, pp. 299-309	
	Abstract of Article – <i>Localization of heparin binding activity in recombinant laminin G domain</i> , U. Sung, J. J. O'Rear, and P. D. Yurchenco from ncbi.nlm.nih.gov (1 page) originally in Eur. J. Biochem., Vol. 250, No. 1, November 15, 1997, pp. 138-143	



Information Disclosure Statement List By Applicant(s) Under 37 CFR Section 1.98(a) (1) (Use several sheets if necessary)	Attorney Docket Number: CXU-407	Serial Number: 10/817,423
	Applicant: Scott, et al.	
	Filing Date: April 2, 2004 Confirmation No: 1563	Group Art Unit: 1646

	Abstract of Article – <i>Molecular cloning of the cDNA encoding human laminin A chain</i> , T. Haaparanta, J. Uitto, E. Ruoslahti, and E. Engvall from <a href="http://ncbi.nlm.nih.gov">ncbi.nlm.nih.gov</a> (2 pages) originally in Matrix, Vol. 11, No. 3, June 1991, pp. 151-160		
	Abstract of Article – <i>The integrin alpha 6 beta 1 promotes the survival of metastatic human breast carcinoma cells in mice</i> , U. M. Wewer, L. M. Shaw, R. Albrechtsen, and A. M. Mercurio from <a href="http://ajp.amjpathol.org">ajp.amjpathol.org</a> (3 pages) originally in American Journal of Pathology, Vol. 151, No. 5, 1997, pp. 1191-1198		
	Article – <i>A Unique Sequence of the Laminin alpha 3 G Domain Binds to Heparin and Promotes Cell Adhesion through Syndecan-2 and -4</i> , Atsushi Utani, Motoyoshi Nomizu, Hiroshi Matsuura, Kozue Kato, Takashi Kobayashi, Ushio Takeda, Shinichi Aota, Peter K. Nielsen, and Hiorshi Shinkai, from <a href="http://jbc.org">jbc.org</a> (21 pages) originally in J. Biol. Chem., Vol. 276, Issue 31, August 3, 2001, pp. 28779-28788		
	Article – <i>Differential Regulation of Cellular Adhesion and Migration by Recombinant Laminin-5 Forms With Partial Deletion or Mutation Within the G3 Domain of alpha 3 Chain</i> , Yoshinobu Kariya, Toshiaki Tsubota, Tomomi Hirosaki, Hiroto Mizushima, Wilma Puzon-McLaughlin, Yoshikazu Takada, and Kaoru Miyazaki, Journal of Cellular Biochemistry, Vol. 88, 2003, pp. 506-520		
	Article – <i>Identification of Integrin-dependent and -independent Cell Adhesion Domains in COOH-Terminal Globular Region of Laminin-5 alpha 3 Chain</i> , Hiroto Mizushima, Hiroyuki Takamura, Yohei Miyagi, Yamato Kikkawa, Naoki Yamanaka, Hidetaro Yasumitsu, Kazuaki Misugi, and Kaoru Miyazaki, Cell Growth & Differentiation, Vol. 6, September 1997, pp. 979-987		
	Article – <i>Isolation and Activity of Proteolytic Fragment of Laminin-5 alpha 3 Chain</i> , Yoshiaki Tsubota, Hiroto Mizushima, Tomomi Hirosaki, Shouichi Higashi, Hidetaro Yasumitsu, and Kaoru Miyazaki, Biochemical and Biophysical Research Communications, Vol. 278, 2000, pp. 614-620		



Information Disclosure Statement List By Applicant(s) Under 37 CFR Section 1.98(a) (1) (Use several sheets if necessary)	Attorney Docket Number: CXU-407	Serial Number: 10/817,423
	Applicant: Scott, et al.	
	Filing Date: April 2, 2004 Confirmation No: 1563	Group Art Unit: 1646

	Article – <i>Processing of Laminin-5 and Its Functional Consequences: Role of Plasmin and Tissue-type Plasminogen Activator</i> , Lawrence E. Goldfinger, M. Sharon Stack, and Jonathan C. R. Jones from jcb.org (28 pages) originally in J. Cell Biol., Vol. 141, No. 1, April 6, 1998, pp. 255-265		
	Article – <i>Reversion of the Malignant Phenotype of Human Breast Cells in Three-Dimensional Culture and In Vivo by Integrin Blocking Antibodies</i> , V. M. Weaver, O. W. Petersen, F. Wang, C. A. Larabell, P. Briand, C. Damsky, and M. J. Bissell from jcb.org (35 pages) originally in J. Cell Biol., Vol. 137, No. 1, April 7, 1997, pp. 231-245		
	Article – <i>Spatial Regulation and Activity Modulation of Plamin by High Affinity Binding to the G domain of the <math>\alpha_3</math> Subunit of Laminin-5</i> , Lawrence E. Goldfinger, Luohua Jiang, Susan B. Hopkinson, M. Sharon Stack, and Jonathan C. R. Jones from jbc.org (14 pages) originally in J. Biol. Chem., Vol. 275, Issue 45, November 10, 2000, pp. 34887-34893		
	Article – <i>Synthetic Peptides Inhibit Adhesion of Human Tumor Cells to Extracellular Matrix Proteins</i> , Ian B. DeRoock, Michael E. Pennington, Thomas C. Sroka, Kit S. Lam, G. Tim Bowden, Elisabeth L. Bair, and Anne E. Cress from cancerres.aacrjournals.org (15 pages) originally in Cancer Research, Vol. 61, April 15, 2001, pp. 3308-3313		
	Article – <i>The LG3 Module of Laminin-5 Harbors a Binding Site for Integrin <math>\alpha_3\beta_1</math> That Promotes Cell Adhesion, Spreading, and Migration</i> , Meiling Shang, Naohiko Koshikawa, Susann Schenk, and Vito Quaranta from jbc.org (21 pages) originally in J. Biol. Chem., Vol. 276, Issue 35, August 31, 2001, pp. 33045-33053		
	Article – <i>The SFL activity secreted by metastatic carcinoma cells is related to laminin 5 and mediates cell scattering in an integrin-independent manner</i> , M. Grassi, G. Moens, P. Rousselle, J. P. Thiéry, and J. Jouanneau, Journal of Cell Science, Vol. 112, 1999, pp. 2511-2520		
	Article – <i>The <math>\alpha 4(IV)</math> Chain of Basement Membrane Collagen</i> , Mariko Mariyama, Raghuram Kalluri, Billy G. Hudson, and Stephen T. Reeders, The Journal of Biological Chemistry, Vol. 267, No. 2, January 15, 1992, pp. 1253-1258		



(Rev. 5/92) Information Disclosure Statement List By Applicant(s) Under 37 CFR Section 1.98(a) (1) (Use several sheets if necessary)	Attorney Docket Number: CXU-407	Serial Number: 10/817,423
	Applicant: Scott, et al.	
	Filing Date: April 2, 2004 Confirmation No: 1563	Group Art Unit: 1646

	Information on Laminin A from sdb.bio.purdue.edu, 3 pages		
	Paper entitled "Basic Integrin Info", May 5, 1997, from integrins.hypermart.net, 3 pages		
	Paper entitled "Perturbation of b1-integrin function alters the development of murine mammary gland" by Marina Glukhova, January 1999, Institut Curie, France, from mammary.nih.gov, 3 pages		
	Research Papers entitled "Integrin Receptor Activation in Breast Cancer", by David Rose, D.V.M., Ph.D. from cbcrcp.org (3 pages)		
	Summary of Article - <i>Rather Rapid Genomic Prep</i> , Gene, Vol. 87, 1987, pp. 262-272		
EXAMINER		DATE CONSIDERED	
Examiner: initial if citation considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.			